Compare TNXP & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNXP | ORMP |
|---|---|---|
| Founded | 2007 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 192.9M | 165.3M |
| IPO Year | 2008 | 2010 |
| Metric | TNXP | ORMP |
|---|---|---|
| Price | $12.32 | $4.61 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 567.5K | 470.5K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | ★ 6.51% |
| EPS Growth | 91.75 | ★ 412.50 |
| EPS | N/A | ★ 0.91 |
| Revenue | ★ $13,107,000.00 | $2,000,000.00 |
| Revenue This Year | $558.11 | N/A |
| Revenue Next Year | $38.29 | N/A |
| P/E Ratio | ★ N/A | $5.05 |
| Revenue Growth | 29.85 | ★ 49.25 |
| 52 Week Low | $10.03 | $1.98 |
| 52 Week High | $69.65 | $5.19 |
| Indicator | TNXP | ORMP |
|---|---|---|
| Relative Strength Index (RSI) | 49.93 | 60.43 |
| Support Level | $12.08 | $3.69 |
| Resistance Level | $13.17 | $5.10 |
| Average True Range (ATR) | 0.87 | 0.32 |
| MACD | 0.15 | 0.08 |
| Stochastic Oscillator | 61.08 | 58.74 |
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.